<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">University of Dundee The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Antoni</forename><forename type="middle">;</forename><surname>Núñez</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Julio</forename><forename type="middle">;</forename><surname>Zannad</surname></persName>
						</author>
						<author>
							<persName><roleName>João</roleName><forename type="first">Faiez</forename><forename type="middle">;</forename><surname>Ferreira</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pedro</forename><forename type="middle">;</forename><surname>Anker</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">D ;</forename><surname>Cleland</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>MD</roleName><forename type="first">Antoni</forename><surname>Bayes-Genis</surname></persName>
							<email>abayesgenis@gmail.com.4</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution" key="instit1">) Heart Institute</orgName>
								<orgName type="institution" key="instit2">Hospital Universitari Germans Trias i Pujol</orgName>
								<address>
									<settlement>Badalona</settlement>
									<country>Spain,</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">CIBERCV</orgName>
								<orgName type="institution" key="instit2">Autonomous University of Barcelona</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country>Spain; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Júlio</forename><surname>Núñez</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Cardiology Department. Hospital Clínico Universitario</orgName>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Departamento de Medicina</orgName>
								<orgName type="institution" key="instit1">INCLIVA</orgName>
								<orgName type="institution" key="instit2">Universitat de València. València</orgName>
								<address>
									<country>Spain; CIBERCV; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Faiez</forename><surname>Zannad</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Inserm, Centre d&apos;Investigation Clinique Plurithématique</orgName>
								<orgName type="department" key="dep2">Inserm U1116</orgName>
								<orgName type="institution" key="instit1">Université de Lorraine</orgName>
								<orgName type="institution" key="instit2">CHRU de Nancy</orgName>
								<orgName type="institution" key="instit3">CRIN INI-CRCT</orgName>
								<address>
									<postCode>1433, F</postCode>
									<settlement>Nancy</settlement>
									<country>France; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">João</forename><forename type="middle">Pedro</forename><surname>Ferreira</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Inserm, Centre d&apos;Investigation Clinique Plurithématique</orgName>
								<orgName type="department" key="dep2">Inserm U1116</orgName>
								<orgName type="institution" key="instit1">Université de Lorraine</orgName>
								<orgName type="institution" key="instit2">CHRU de Nancy</orgName>
								<orgName type="institution" key="instit3">CRIN INI-CRCT</orgName>
								<address>
									<postCode>1433, F</postCode>
									<settlement>Nancy</settlement>
									<country>France; (</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Physiology and Cardiothoracic Surgery</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="laboratory">Cardiovascular Research and Development Unit</orgName>
								<orgName type="institution">University of Porto</orgName>
								<address>
									<settlement>Porto</settlement>
									<country>Portugal; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Anker</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Division of Cardiology and Metabolism -Heart Failure</orgName>
								<orgName type="department" key="dep2">Department of Cardiology (CVK)</orgName>
								<orgName type="institution">Cachexia &amp; Sarcopenia</orgName>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">Berlin-Brandenburg Center for Regenerative Therapies (BCRT)</orgName>
								<orgName type="institution">Charité University Medicine</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medicine Göttingen (UMG)</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country>Germany &amp;</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">DZHK (German Center for Cardiovascular Research)</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">John</forename><forename type="middle">G</forename><surname>Cleland</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution" key="instit1">National Heart &amp; Lung Institute</orgName>
								<orgName type="institution" key="instit2">Royal Brompton &amp; Harefield Hospitals</orgName>
								<orgName type="institution" key="instit3">Imperial College</orgName>
								<address>
									<settlement>London</settlement>
									<country>United Kingdom; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Kenneth</forename><surname>Dickstein</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution" key="instit1">University of Bergen</orgName>
								<orgName type="institution" key="instit2">Stavanger University</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Gerasimos</forename><surname>Filippatos</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">School of Medicine</orgName>
								<orgName type="department" key="dep2">Department of Cardiology</orgName>
								<orgName type="department" key="dep3">Heart Failure Unit</orgName>
								<orgName type="institution">) National and Kapodistrian University of Athens</orgName>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="institution">Athens University Hospital Attikon</orgName>
								<address>
									<settlement>Athens</settlement>
									<country>Greece; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Chim</forename><forename type="middle">C</forename><surname>Lang</surname></persName>
							<affiliation key="aff15">
								<orgName type="department" key="dep1">School of Medicine Centre for Cardiovascular and Lung Biology</orgName>
								<orgName type="department" key="dep2">Division of Medical Sciences</orgName>
								<orgName type="institution" key="instit1">University of Dundee</orgName>
								<orgName type="institution" key="instit2">Ninewells Hospital &amp; Medical School</orgName>
								<address>
									<settlement>Dundee</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Leong</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><surname>Ng</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Piotr</forename><surname>Ponikowski</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Nilesh</forename><forename type="middle">J</forename><surname>Samani</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Dirk</forename><forename type="middle">J</forename><surname>Van Veldhuisen</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">University of Groningen</orgName>
								<address>
									<settlement>Groningen</settlement>
									<country>the Netherlands; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Aeilko</forename><forename type="middle">H</forename><surname>Zwinderman</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Epidemiology, biostatistics &amp; bioinformatics</orgName>
								<orgName type="institution">Academic Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country>The Netherlands; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Marco</forename><surname>Metra</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Medical and Surgical Specialties</orgName>
								<orgName type="institution">Radiological Sciences and Public Health, university of Brescia Italy</orgName>
								<address>
									<settlement>Cardiology</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Josep</forename><surname>Lupón</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="institution" key="instit1">) Heart Institute</orgName>
								<orgName type="institution" key="instit2">Hospital Universitari Germans Trias i Pujol</orgName>
								<address>
									<settlement>Badalona</settlement>
									<country>Spain,</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">CIBERCV</orgName>
								<orgName type="institution" key="instit2">Autonomous University of Barcelona</orgName>
								<address>
									<settlement>Barcelona</settlement>
									<country>Spain; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Cardio3Biosciences, Celladon, GSK, Merck/MSD</roleName><forename type="first">Boehringer</forename><surname>Ingelheim</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Inserm, Centre d&apos;Investigation Clinique Plurithématique</orgName>
								<orgName type="department" key="dep2">Inserm U1116</orgName>
								<orgName type="institution" key="instit1">Université de Lorraine</orgName>
								<orgName type="institution" key="instit2">CHRU de Nancy</orgName>
								<orgName type="institution" key="instit3">CRIN INI-CRCT</orgName>
								<address>
									<postCode>1433, F</postCode>
									<settlement>Nancy</settlement>
									<country>France; (</country>
								</address>
							</affiliation>
							<affiliation key="aff22">
								<orgName type="department">Department of Epidemiology, biostatistics &amp; bioinformatics</orgName>
								<orgName type="institution">Academic Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country>The Netherlands; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Novartis, Servier, Stealth Peptides, Singulex, Sphingotec, Trevena, Vifor</roleName><forename type="first">Z</forename><forename type="middle">S</forename><surname>Pharma</surname></persName>
						</author>
						<author>
							<persName><surname>Sda</surname></persName>
						</author>
						<author>
							<affiliation key="aff12">
								<address>
									<settlement>Hospital, Stavanger</settlement>
									<country>Norway; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="department">Department of Cardiovascular Sciences</orgName>
								<orgName type="institution" key="instit1">University of Leicester</orgName>
								<orgName type="institution" key="instit2">Glenfield Hospital</orgName>
								<address>
									<settlement>Leicester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff17">
								<orgName type="institution">NIHR Leicester Biomedical Research Centre</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff18">
								<orgName type="institution">Glenfield Hospital</orgName>
								<address>
									<postCode>LE3 9QP</postCode>
									<settlement>Leicester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff19">
								<orgName type="department">and Cardiology Department</orgName>
								<orgName type="institution">Wroclaw Medical University</orgName>
								<address>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff20">
								<orgName type="institution">Military Hospital</orgName>
								<address>
									<settlement>Wroclaw</settlement>
									<country>Poland; (</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="department">FESC. Head</orgName>
								<orgName type="institution">Heart Institute. Hospital Universitari Germans Trias i Pujol. Carretera de Canyet s/n 08916. Badalona (Barcelona)</orgName>
								<address>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">University of Dundee The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">D6BF7CF82A800FF84D3D6D5E5AC56B5C</idno>
					<idno type="DOI">10.1016/j.jacc.2017.08.057</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:32+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Bayer</term>
					<term>Boehringer Ingelheim</term>
					<term>Brahms</term>
					<term>Janssen</term>
					<term>Novartis</term>
					<term>Servier</term>
					<term>Proprotein convertase subtilisin/kexin type 9 (PCSK9)</term>
					<term>low-density lipoprotein receptor (LDLR)</term>
					<term>heart failure</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Zeneca, MSD, Novartis, and Servier.</s><s>DVV received board membership fees or travel expenses from Novartis, Johnson &amp; Johnson, and Vifor.</s><s>MM has received consulting honoraria from Amgen, Astra-Zeneca, Bayer, Novartis, Relypsa, Servier, Stealth therapeutics, and Trevena and speaker's fees from Abbott Vascular and Servier All other authors declare no conflict of interest.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Major advances in heart failure (HF) management have been achieved over the last three decades by targeting two main pathways activated in HF, namely the reninangiotensin-aldosterone system and the sympathetic nervous system <ref type="bibr" target="#b0">(1)</ref><ref type="bibr" target="#b2">(2)</ref><ref type="bibr" target="#b3">(3)</ref><ref type="bibr" target="#b4">(4)</ref><ref type="bibr" target="#b5">(5)</ref>.</s></p><p><s>Nevertheless, HF remains a syndrome with high morbidity and mortality, poor quality of life, and high health-care costs <ref type="bibr" target="#b6">(6)</ref>.</s></p><p><s>Targeting alternative pathways that participate in the HF syndrome seem the next logical approach.</s><s>One such pathway is atherosclerosis progression; however, the administration of statins in HF has led to debatable results.</s><s>Indeed, the two major randomized trials that studied the effect of statin treatment in patients with chronic HF did not demonstrate sufficient evidence of benefit <ref type="bibr" target="#b7">(7,</ref><ref type="bibr" target="#b8">8)</ref>.</s><s>However, at least in CORONA the secondary endpoint of heart failure hospitalization was significantly reduced by rosuvastatin <ref type="bibr" target="#b7">(7)</ref>.</s><s>Also, some reports on real-life data have shown a positive association between statins and outcomes <ref type="bibr" target="#b9">(9)</ref>.</s></p><p><s>A new biotarget for treating atherosclerosis progression is proprotein convertase subtilisin/kexin type 9 (PCSK9) <ref type="bibr" target="#b10">(10,</ref><ref type="bibr" target="#b12">11)</ref>.</s><s>Secreted into the plasma by the liver, PCSK9 binds the low-density lipoprotein (LDL) receptor (LDLR) at the surface of hepatocytes.</s><s>This binding prevents LDLR recycling and enhances its degradation in endosomes and lysosomes, which results in reduced LDL-cholesterol clearance <ref type="bibr" target="#b13">(12)</ref>.</s><s>The recent Glavov <ref type="bibr" target="#b14">(13)</ref> and Fourier <ref type="bibr" target="#b16">(14)</ref> studies have demonstrated that PCSK9 inhibition with monoclonal antibodies could reduce the atherosclerosis disease burden and cardiovascular events.</s></p><p><s>The potential of PCSK9 as a biotarget in HF is unknown.</s><s>Herein, we hypothesized that, similar to what was shown in patients with coronary artery disease, elevated levels of PCSK9 in HF are associated with outcomes.</s><s>Accordingly, we aimed to decipher the value of the PCSK9-LDLR axis for predicting risk in patients with HF in the multicenter BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) cohort <ref type="bibr" target="#b17">(15)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BIOSTAT-CHF Cohort</head><p><s>The BIOSTAT-CHF was a multicenter, multinational, prospective, observational study that included 2516 patients with worsening signs and/or symptoms of HF from 69 centers in 11 European countries.</s><s>The recruitment period was 24 months, from December 2010 to December 2012 <ref type="bibr" target="#b17">(15)</ref>.</s><s>The median follow-up was 21months</s></p><p><s>[interquartile range (IQR) 15-27months].</s><s>The Ethics Committees of participating institutions approved this study, and all patients provided written consent to participate in the study.</s></p><p><s>Eligible patients, exclusion criteria, and characteristics of the BIOSTAT-CHF cohort have been described elsewhere <ref type="bibr" target="#b17">(15)</ref>.</s><s>In brief, the majority of patients were hospitalized for acute HF, and the remainder presented with worsening signs and/or symptoms of HF at outpatient clinics.</s><s>Approximately half of the patients were classified as New York Heart Association class III.</s><s>Blood was drawn within days of the worsening HF event (either in-or outpatient).</s></p><p><s>All deaths and hospitalizations were recorded.</s><s>The primary outcomes of interest were the time to all-cause mortality and the time to a composite of death or unscheduled hospitalization for HF.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PCSK9 and LDL Receptor Assays.</head><p><s>PCSK9 and LDLR were measured using the Proseek ® Multiplex CVDIII panel (Olink Proteomics AB, Uppsala, Sweden) according to the manufacturer's instructions.</s><s>The Proximity Extension Assay (PEA) technology used for the Proseek ® Multiplex protocol has been well described <ref type="bibr" target="#b20">(16)</ref>.</s><s>In brief, pairs of oligonucleotide-labeled antibody probes bind to their targeted protein, and if the two probes are brought in close proximity the oligonucleotides will hybridize in a pair-wise manner.</s><s>The addition of a DNA polymerase leads to a proximity-dependent DNA polymerization event, generating a unique PCR target sequence.</s><s>The resulting DNA sequence is subsequently detected and quantified using a microfluidic real-time PCR instrument (Biomark HD, Fluidigm).</s></p><p><s>Data is then quality controlled and normalized using an internal extension control and an inter-plate control, to adjust for intra-and inter-run variation.</s><s>The final assay readout is presented in Normalized Protein eXpression (NPX) values, which is an arbitrary unit on Log2 scale where a high value corresponds to a higher protein expression.</s><s>All assay validation data (detection limits, intra-and inter-assay precision data, etc) are available on manufacturer's website (www.olink.com).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Continuous variables are expressed as the mean ± standard deviation (SD) or the median (IQR) per variable distribution.</s><s>Discrete variables are presented as percentages.</s></p><p><s>Baseline characteristics among PSCK9 and LDLR quartiles were compared with ANOVA, Kruskall-Wallis, or chi-squared tests, as appropriate.</s></p><p><s>The bivariate correlation of the two exposures was assessed with Spearman's rank correlation coefficient.</s><s>A multivariable linear regression analysis was performed to determine the association of LDLR with PCSK9 while adjusting for age, gender, ischemic heart disease, LDL-cholesterol, HDL-cholesterol, and eGFR.</s></p><p><s>The Cox proportional hazard regression was used to determine the simultaneously-adjusted effect of PCSK9 and LDLR on all-cause mortality and on the composite of mortality and HF hospitalization.</s><s>Each of these models included as covariates the use of statins and tertiles of the previously derived BIOSTAT risk score 9 <ref type="bibr" target="#b22">(17)</ref>.</s><s>Briefly, the BIOSTAT risk score for each endpoint was calculated as the probability of achieving the endpoint at a 2-year follow-up.</s><s>The BIOSTAT risk score for mortality included age, blood urea nitrogen, NT-proBNP, serum hemoglobin, and the use of a beta-blocker.</s><s>The BIOSTAT risk score for the composite endpoint included age, previous HF-related hospitalization, the presence of edema, systolic blood pressure, and the estimated glomerular filtration rate <ref type="bibr" target="#b22">(17)</ref>.</s><s>Results are expressed as hazard ratios (HR) with their respective 95% CI.</s><s>The proportionality assumptiontested by means of the Schoenfeld residuals -was met for all models.</s><s>In a sensitivity analysis, LDL cholesterol was added as an additional covariate to the previous prognostic models.</s></p><p><s>Measures of performance were assessed by means of  C-statistics, integrated discrimination improvement (IDI), and net reclassification improvement (NRI)(%).</s><s>In order to match the scope of the BIOSTAT risk score, these indices were calculated at a horizon of 2 years.</s><s>Two variations of the analysis are presented: 1) PCSK9, LDLR, and the use of statins are compared over the BIOSTAT risk score alone, and 2) PCSK9 is contrasted against LDLR, use of statins, and the BIOSTAT risk score.</s></p><p><s>We set a two-sided p-value of &lt;0.05 as the threshold for statistical significance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>A total of 2174 patients were included in this analysis (Online Figure <ref type="figure" target="#fig_3">1</ref>).</s><s>The mean age of the sample was 68 ± 12 years; 581 (49.7%) were female, 1156 (53.2%) had history of ischemic heart disease, and 1727 (88.8%) exhibited LVEF ≤40% (4.5% had LVEF in the mid-range and 6.7% had preserved LVEF).</s><s>The median (IQR) values of PCSK9, LDLR, and NT-proBNP were 1.81U/mL (1.45-2.18),</s><s>2.98 U/mL (2.45-3.53),</s><s>and 4148 pg/mL (2330-8136), respectively.</s><s>The baseline values of PCSK9 and LDLR across quartiles are shown in Tables <ref type="table" target="#tab_1">1 and 2</ref>. Overall, patients in the higher PCSK9 quartiles displayed a higher prevalence of ischemic heart disease and prior coronary revascularization and higher values of creatinine, and potassium (Table <ref type="table" target="#tab_0">1</ref>).</s><s>In contrast, the disease severity surrogates were inversely related to the LDLR quartiles.</s><s>Indeed, those in the lower LDLR quartiles were older, more frequently males, and exhibited higher proportions of prior renal failure and atrial fibrillation.</s><s>Similarly, the lower LDLR quartile displayed lower systolic blood pressure and hemoglobin, and higher values of urea and NT-proBNP (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Regarding medications, higher proportions of patients used statins in the upper quartiles of the two studied exposures.</s><s>(Tables <ref type="table" target="#tab_1">1, 2</ref>).</s><s>LVEF categories, as defined in the ESC Guidelines (1), were similarly distributed across PCSK9 and LDLR quartiles (p=0.365 and p=0.193, respectively).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Circulating PCSK9 predictors</head><p><s>Online Figure <ref type="figure" target="#fig_4">2</ref> shows the identified predictors of circulating PCSK9 levels.</s><s>The model's adjusted R-squared was 0.422.</s><s>A closer look at the positive correlation between PCSK9 and LDLR is depicted in Online Figure <ref type="figure">3</ref> (r = 0.59; p&lt;0.001).</s><s>Exploratory analyses across NT-proBNP quartiles with PCSK9 and LDLR did not show prognostic differences on all-cause mortality or the composite endpoint.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Mortality endpoint</head><p><s>During a median follow-up of 1.78 years (IQR: 1.29-2.25),</s><s>569 deaths (26.2%) were registered.</s><s>Multivariable analysis that included as covariates the BIOSTAT risk score for mortality, LDLR, and statin treatment, revealed a positive linear association between PCSK9 and the risk of mortality (p=0.020; Figure <ref type="figure" target="#fig_3">1A</ref>).</s><s>A similar analysis revealed a negative linear association between LDLR and mortality (p=0.025; Figure <ref type="figure" target="#fig_3">1B</ref>).</s><s>The estimated HRs from regression modeling are shown in Table <ref type="table">3</ref>.</s><s>Since PCSK9 and LDLR levels were highly correlated, we excluded one exposure at a time to assess -on the other one-if multicollinearity was artificially changing in the direction of the effect.</s></p><p><s>Under this premise, a positive association for all-cause mortality was confirmed for PCSK9 and a negative one for LDLR (results not shown).</s><s>Indeed, both variables' linear trajectories showed opposite directions, with increasing risk at higher PCSK9 levels and lower risk at higher LDLR levels (Figure <ref type="figure" target="#fig_3">1</ref>).</s></p><p><s>In exploratory fashion, several interactions were tested, all with negative results:</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Composite endpoint</head><p><s>At a median follow-up of 1.53 years (IQR, 0.67-2.15),</s><s>we ascertained 896 (41.2%) composite endpoints (composite of death or HF-related hospitalization).</s><s>In a multivariable context, PCSK9 showed a linear and positive association with the risk of the combined endpoint (p=0.011; Figure <ref type="figure" target="#fig_4">2A</ref>), independent of the effect of BIOSTAT risk score for the composite endpoint, LDLR, and statin treatment; LDLR, however, showed a negative but borderline association (p=0.087; Figure <ref type="figure" target="#fig_4">2B</ref>).</s><s>The estimated HRs from regression modeling are shown in Table <ref type="table">3</ref>.</s><s>The direction of the effect for both PCSK9 and LDLR were confirmed by excluding one of them at a time to rule-out changes due to multicollinearity.</s></p><p><s>In exploratory fashion, several interactions were tested, all with negative results:</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sensitivity analysis</head><p><s>In a sensitivity analysis, where plasma LDL cholesterol was added as an additional covariate, the results were consistent with the main findings, despite a drop in sample numbers (n=1000), due to missing LDL cholesterol values.</s><s>Circulating PCSK9 and LDLR levels were independently associated with mortality risk and the composite endpoint (Online Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>The present report is the first to show that the PCSK9-LDLR axis was associated with poor outcomes in patients with HF.</s><s>Our sub-analysis of the BIOSTAT-CHF cohort indicated that soluble PCSK9 was positively associated with both all-cause mortality and the composite endpoint of mortality or HF-related rehospitalizations in patients with worsening HF.</s><s>By contrast, as pathobiologically expected, circulating LDLR was inversely associated with the same two endpoints.</s><s>Interestingly, the predictive value of PCSK9 improved after adjusting for traditional prognosticators and soluble LDLR.</s></p><p><s>The predictive value of circulating PCSK9 concentrations was previously described in other clinical settings of cardiovascular pathology <ref type="bibr" target="#b26">(19)</ref><ref type="bibr" target="#b28">(20)</ref>.</s><s>In the context of HF, a comprehensive multivariable analysis with validated BIOSTAT risk scores showed that higher PCSK9 was associated with an increased incidence of the composite endpoint, and this relationship was independent of serum LDL cholesterol, statin use, or ischemic HF etiology.</s><s>Thus, PCSK9 may be considered a risk predictor across the cardiovascular disease continuum, from asymptomatic dyslipidemia, through subclinical and clinical atherosclerosis, and in HF, based on our findings (Central Illustration).</s></p><p><s>Secreted PCSK9 follows two possible tracks: the first is to bind immediately to LDLRs in the liver, and the second is to enter the systemic circulation <ref type="bibr" target="#b13">(12)</ref>.</s><s>Once bound, the PCSK9/LDLR complex is endocytosed, taken into the lysosomes, and undergoes degradation <ref type="bibr" target="#b30">(21)</ref>.</s><s>The presence of PCSK9 enhances LDLR degradation; therefore this track reduces the LDLR abundance on the cell surface <ref type="bibr" target="#b32">(22)</ref>.</s><s>In the plasma, circulating PCSK9 can bind to LDLRs on the membranes of various organ systems, such as the liver, intestines, kidneys, lungs, pancreas, and adipose tissues <ref type="bibr" target="#b34">(23)</ref><ref type="bibr" target="#b36">(24)</ref><ref type="bibr" target="#b38">(25)</ref><ref type="bibr" target="#b40">(26)</ref><ref type="bibr" target="#b41">(27)</ref>.</s><s>In the present report, although the ability for risk prediction of PCSK9 and LDLR was opposite when included in comprehensive multivariable models, their circulating concentrations showed a significant positive correlation.</s><s>This finding may reflect the already recognized complexity of the PCSK9-LDLR axis <ref type="bibr" target="#b42">(28)</ref>.</s><s>Indeed, Tavori et al report that in addition to the straightforward mechanism of action (PCSK9 terminating the lifecycle of LDLR), there are more complex interactions between PCSK9, LDLR and plasma lipoprotein levels, including: (a) the presence of both parallel and reciprocal regulation of surface LDLR and plasma PCSK9; (b) a correlation between PCSK9 and LDL cholesterol levels dependent not only on the fact that PCSK9 removes hepatic LDLR, but also due to the fact that up to 40% of plasma PCSK9 is physically associated with LDL; and (c) an association between plasma PCSK9 production and the assembly and secretion of triglyceride-rich lipoproteins <ref type="bibr" target="#b42">(28)</ref>.</s></p><p><s>Despite numerous advances in HF treatments, which block both the sympathetic nervous system and the renin-angiotensin-aldosterone system, the morbidity and mortality of patients with HF remain unacceptably high <ref type="bibr" target="#b43">(29)</ref>.</s><s>Our finding that PCSK9 could predict risk in HF may serve as a basis for designing prospective studies that aim to inhibit PCSK9, either with specific PCSK9 neutralizing monoclonal antibodies or with the administration of small, interfering RNAs (siRNAs) that specifically bind and inhibit translation of PCSK9 mRNAs <ref type="bibr" target="#b14">(13,</ref><ref type="bibr" target="#b16">14,</ref><ref type="bibr" target="#b45">30)</ref>.</s></p><p><s>In patients with acute coronary syndromes, the potential benefit of treatment with PCSK9 antibodies may be two-fold, because it could both reduce LDL cholesterol and stabilize plaques <ref type="bibr" target="#b10">(10)</ref>.</s><s>Indeed, PCSK9 adversely affects coronary plaques through several pathways, including proinflammatory LDL oxidation and direct modification of plaque composition.</s><s>Moreover, PCSK9 is associated with the inflammatory response, which is largely based on NF-κB-mediated expression of proinflammatory genes, including cytokines, chemokines, and adhesion molecules <ref type="bibr" target="#b47">(31,</ref><ref type="bibr" target="#b48">32)</ref>.</s><s>The PCSK9-induced NF-κB pathway can upregulate tissue factor expression, which enhances the thrombotic substrate in atherosclerotic plaques <ref type="bibr" target="#b49">(33)</ref>.</s><s>In the context of HF, it is reasonable to speculate that plaque stabilization, combined with reductions in the prothrombotic and proinflammatory states, accomplished by inhibiting PCSK9, might represent a new avenue of treatment for preventing disease progression, when the current optimal medical treatment is insufficient.</s><s>It is unclear whether this strategy will be useful across all HF etiologies, or only for those of ischemic origin; this issue should be investigated in future, well-designed, prospective clinical trials.</s></p><p><s>Two randomized clinical trials that explored reducing cholesterol levels with rosuvastatin in patients with HF did not demonstrate a clear benefit <ref type="bibr" target="#b7">(7,</ref><ref type="bibr" target="#b8">8)</ref>.</s><s>Rosuvastatin is a hydrophilic statin, which relies on active transport into hepatocytes to exert its effect and has poor penetration into extrahepatic tissues; thus, it has less risk of adverse effects but also very low uptake by cardiac muscle.</s><s>No randomized studies have been performed with lipophilic statins (simvastatin, atorvastatin), which tend to achieve higher levels of exposure in nonhepatic tissues, have very high cardiac muscle uptake, and in real-life scenarios have shown some benefit <ref type="bibr" target="#b9">(9,</ref><ref type="bibr" target="#b50">34)</ref>.</s><s>Current guidelines do not recommend the use of statins in patients with HF (1).</s><s>Whether interfering with cholesterol-related mechanistic pathway may be beneficial in selected patients with HF is not a totally settled issue <ref type="bibr" target="#b51">(35)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations:</head><p><s>The current study had some limitations.</s><s>First, the data presented here are valid for patients with worsening HF, mainly due to reduced LVEF.</s><s>It remains to be determined whether soluble PCSK9 is also a good predictor for patients with stable chronic HF.</s><s>Currently available data in the context of coronary artery disease showed in mice that plasma PCSK9 concentration was mostly elevated in the early hours after an acute coronary syndrome <ref type="bibr" target="#b53">(36)</ref>.</s><s>The second limitation was that the assay used to measure PCSK9 and LDLR was designed for research only, and its use cannot be recommended in clinical practice.</s><s>Nevertheless, both exposures were measured with state-of-the art proteomics technology, currently available and well validated <ref type="bibr" target="#b20">(16)</ref>.</s><s>The last limitation was that genetic mutations that might determine PCSK9 levels were not measured in patients enrolled in the BIOSTAT-CHF trial.</s><s>PCSK9 gain-of-function mutations have been associated with increased severity in coronary atherosclerosis <ref type="bibr" target="#b54">(37)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p><s>The PCSK9-LDLR axis has been investigated expeditiously, from discovery to targeted therapy, in dyslipidemia and coronary atherosclerosis.</s><s>Here, we provided the first evidence of PCSK9 participation in HF.</s><s>Indeed, HF risk was positively associated with circulating PCSK9 and negatively associated with LDLR in patients with worsening HF.</s><s>Future studies are needed to better understand the PCSK9-LDLR axis in HF, and to assess whether PCSK9 inhibition or silencing might lead to better outcomes in HF.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PERSPECTIVES</head><p><s>Competency in Medical Knowledge: Proprotein convertase subtilisin/kexin type 9 (PCSK9), which binds the low-density lipoprotein receptor (LDLR) and prevents its recycling, is a risk predictor and biotarget in atherosclerosis progression.</s><s>Here, we demonstrated that HF risk was positively associated with circulating PCSK9 and negatively associated with LDLR levels.</s></p><p><s>Translational Outlook: Our data provided a basis for future research to investigate whether HF outcomes might be improved by inhibiting PCSK9, either with specific PCSK9-neutralizing monoclonal antibodies or with small interfering RNAs (siRNAs).</s><s>Central Illustration: PCSK9 across the cardiovascular continuum.</s><s>In heart failure we proved evidence of elevated PCSK9 levels, which were associated with poor outcomes.</s><s>There is no evidence of PCSK9 inhibition in HF.</s></p><note type="other">FIGURE LEGENDS</note></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Stata 14 . 2 (</head><label>142</label><figDesc><div><p><s>Stata Statistical Software, Release 14 [2015]; StataCorp LP, College Station, TX, USA), was used for the main analysis.</s><s>Risk reclassification analyses were implemented in R (Version 3.40; R Foundation for Statistical Computing, Vienna, Austria) with the survIDINRI and SurvC1 modules.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>PCSK9 quartiles vs LDLR (p = 0.388); LDLR quartiles vs PCSK9 (p = 0.143); statins vs PCSK9 (p = 0.432); statins vs LDLR (p = 0.860); ischemic heart disease vs PCSK9 (p = 0.271); and ischemic heart disease vs LDLR (p = 0.079).</s><s>The added value in performance for PCSK9, LDLR, and statin treatment over the BIOSTAT risk score was confirmed by  C-statistic [0.0120 (0.002-0.022); p=0.019],</s><s>IDI [0.3 (0-1.1)], and NRI [6.0 (0-11.9)].</s><s>Similarly, PCSK9 produced a better risk reclassification over LDLR, statin treatment, and the BIOSTAT risk score as evidenced by IDI [0.6 (0.1-1.8)] and NRI [11.0 (1.0-18.3)].</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>PCSK9 quartiles vs LDLR (p = 0.200); LDLR quartiles vs PCSK9 (p = 0.929); statins vs PCSK9 (p = 0.485); statins vs LDLR (p = 0.403); ischemic heart disease vs PCSK9 (p = 0.170); and ischemic heart disease vs LDLR (p = 0.211).</s><s>The added value in performance for PCSK9, LDLR, and statin treatment over the BIOSTAT risk score was confirmed by  C-statistic [0.014 (0.006-0.022): p&lt;0.001],</s><s>IDI [0.8 (0.2-1.8)], and NRI [10.8 (2.9-15.0)].</s><s>Similarly, PCSK9 produced a better risk reclassification over LDLR, statin treatment, and the BIOSTAT risk score both by IDI [0.6 (0-1.5)], and NRI [9.8 (0.4-17.7)].</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 1 :</head><label>1</label><figDesc><div><p><s>Figure 1:Multivariable analyses for all-cause mortality.</s><s>(A) HR-gradient, with the</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 2 :</head><label>2</label><figDesc><div><p><s>Figure 2:Multivariable analyses for the composite endpoint (mortality or HF-</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 :</head><label>1</label><figDesc><div><p><s>Demographic, clinical, laboratory and treatment characteristics relative to PCSK9 quartiles</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell cols="2">PCSK9</cell><cell></cell><cell></cell></row><row><cell></cell><cell>1 st Quartile</cell><cell>2 nd Quartile</cell><cell>3 rd Quartile</cell><cell>4 th Quartile</cell><cell>P value</cell></row><row><cell>Variables</cell><cell>N= 544</cell><cell>N=543</cell><cell>N=544</cell><cell>N=543</cell><cell></cell></row><row><cell>Age, years, mean (sd)</cell><cell>69 (12)</cell><cell>69 (13)</cell><cell>67 (12)</cell><cell>68 (12)</cell><cell>0.08</cell></row><row><cell>Sex, male, n (%)</cell><cell>413 (75.9)</cell><cell>401 (73.8)</cell><cell>391 (71.9)</cell><cell>388 (71.5)</cell><cell>0.32</cell></row><row><cell>Ischemic heart disease, n (%)</cell><cell>273 (50.7)</cell><cell>273 (51.3)</cell><cell>277 (52.7)</cell><cell>333 (61.8)</cell><cell>0.001</cell></row><row><cell>Dilated cardiomypathy, n (%)</cell><cell>167 (30.7)</cell><cell>186 (34.3)</cell><cell>157 (28.9)</cell><cell>156 (28.7)</cell><cell>0.17</cell></row><row><cell>Hypertension, n (%)</cell><cell>347 (63.8)</cell><cell>322 (59.3)</cell><cell>323 (59.4)</cell><cell>355 (65.4)</cell><cell>0.09</cell></row><row><cell>Diabetes mellitus, n (%)</cell><cell>173 (31.8)</cell><cell>172 (31.7)</cell><cell>171 (31.4)</cell><cell>185 (34.1)</cell><cell>0.77</cell></row><row><cell>Renal failure, n (%)</cell><cell>162 (29.8)</cell><cell>153 (28.2)</cell><cell>131 (24.1)</cell><cell>169 (31.1)</cell><cell>0.06</cell></row><row><cell>Atrial fibrillation, n (%)</cell><cell>243 (44.7)</cell><cell>266 (49.0)</cell><cell>254 (46.7)</cell><cell>228 (42.0)</cell><cell>0.12</cell></row><row><cell>Heart rate (bpm), mean (SD)</cell><cell>81 (19)</cell><cell>80 (20)</cell><cell>79 (20)</cell><cell>80 (19)</cell><cell>0.67</cell></row><row><cell>LVEF %, mean (SD) *</cell><cell>32 (11)</cell><cell>30 (10)</cell><cell>31 (10)</cell><cell>31 (11)</cell><cell>0.28</cell></row><row><cell>Laboratory</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hemoglobin (g/dL), mean (SD)</cell><cell>13.0 (1.9)</cell><cell>13.1 (1.8)</cell><cell>13.2 (1.9)</cell><cell>13.4 (2.0)</cell><cell>0.07</cell></row><row><cell>Serum creatinine, mg/dl, mean (SD)</cell><cell>1.28 (0.52)</cell><cell>1.27 (0.53)</cell><cell>1.27 (0.67)</cell><cell>1.38 (0.74)</cell><cell>0.008</cell></row><row><cell cols="5">NT-proBNP (ng/L), median (IQR) 3975 (2288; 7751) 4654 (2364; 8475) 3784 (2242; 8105) 3949 (2360; 8000)</cell><cell>0.61</cell></row><row><cell>LDLc (mmol/L), mean (SD)  ¶</cell><cell>2.54 (0.99)</cell><cell>2.50 (0.98)</cell><cell>2.65 (1.11)</cell><cell>2.67 (1.14)</cell><cell>0.21</cell></row></table><note><p><s>PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low density lipoprotein receptor; LDLc, LDL cholesterol; NTpro-BNP, N-terminus pro B-type natriuretic peptide; MRA, mineralo-receptor antagonists; ACEI, angiotensin coverting-enzyme inhibitors; ARB, angiotensin receptor 2 inhibitors; SD, standard deviation; IQR, interquartile range; bpm, beats per minute.</s><s>U/mL, is a Normalized Protein eXpression (NPX) arbitrary unit (see Methods forr details).</s><s>* data available in 1946 patients; ¶ data available in 1000 patients.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 :</head><label>2</label><figDesc><div><p><s>Demographic, clinical, laboratory and treatment characteristics relative to LDLR quartiles density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLc, LDL cholesterol; NTpro-BNP, N-terminus pro B-type natriuretic peptide; MRA, mineralo-receptor antagonists; ACEI, angiotensin coverting-enzyme inhibitors; ARB, angiotensin receptor 2 inhibitors; SD, standard deviation; IQR, interquartile range; LVEF, left ventricular ejection fraction; bpm, beats per minute.</s><s>U/mL, is a Normalized Protein eXpression (NPX) arbitrary unit (see Methods for details).</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>LDLR</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>1 st Quartile</cell><cell>2 nd Quartile</cell><cell>3 rd Quartile</cell><cell>4 th Quartile</cell><cell>P value</cell></row><row><cell>Variables</cell><cell>N= 544</cell><cell>N=543</cell><cell>N=544</cell><cell>N=543</cell><cell></cell></row><row><cell>Age, years, mean (sd)</cell><cell>70 (12)</cell><cell>69 (12)</cell><cell>68 (12)</cell><cell>66 (12)</cell><cell>&lt; 0.001</cell></row><row><cell>Sex, male, n (%)</cell><cell>425 (78.1)</cell><cell>409 (75.3)</cell><cell>397 (73.0)</cell><cell>362 (66.7)</cell><cell>&lt; 0.001</cell></row><row><cell>Ischemic heart disease, n (%)</cell><cell>280 (52.3)</cell><cell>295 (55.5)</cell><cell>288 (54.0)</cell><cell>293 (54.8)</cell><cell>0.76</cell></row><row><cell>Dilated cardiomypathy, n (%)</cell><cell>154 (28.3)</cell><cell>161 (29.7)</cell><cell>163 (30.0)</cell><cell>188 (34.6)</cell><cell>0.12</cell></row><row><cell>Hypertension, n (%)</cell><cell>349 (64.2)</cell><cell>314 (57.8)</cell><cell>327 (60.1)</cell><cell>357 (65.7)</cell><cell>0.03</cell></row><row><cell>Diabetes mellitus, n (%)</cell><cell>167 (30.7)</cell><cell>162 (29.8)</cell><cell>177 (32.5)</cell><cell>195 (35.9)</cell><cell>0.15</cell></row><row><cell>Renal failure, n (%)</cell><cell>180 (33.1)</cell><cell>153 (28.2)</cell><cell>136 (25.0)</cell><cell>146 (26.9)</cell><cell>0.02</cell></row><row><cell>Atrial fibrillation, n (%)</cell><cell>285 (52.4)</cell><cell>259 (47.7)</cell><cell>250 (46.0)</cell><cell>197 (36.3)</cell><cell>&lt; 0.001</cell></row><row><cell>Heart rate (bpm), mean (SD)</cell><cell>80 (19)</cell><cell>80 (20)</cell><cell>81 (21)</cell><cell>80 (19)</cell><cell>0.94</cell></row><row><cell>LVEF %, mean (SD) *</cell><cell>31 (11)</cell><cell>30 (11)</cell><cell>31 (11)</cell><cell>31 (10)</cell><cell>0.50</cell></row><row><cell>Laboratory</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Hemoglobin (g/dL), mean (SD)</cell><cell>12.8 (1.9)</cell><cell>13.2 (1.9)</cell><cell>13.2 (1.9)</cell><cell>13.5 (1.9)</cell><cell>&lt; 0.001</cell></row><row><cell>Serum creatinine, mg/dl, mean (SD)</cell><cell>1.32 (0.59)</cell><cell>1.28 (0.71)</cell><cell>1.31 (0.60)</cell><cell>1.29 (0.58)</cell><cell>0.66</cell></row><row><cell cols="6">NT-proBNP (ng/L), median (IQR) 4339 (2420; 8068) 5302 (2767; 9449) 3632 (2358; 7340) 3499 (1775; 7337) &lt; 0.001</cell></row><row><cell>Treatment</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>* data available in 1946 patients; ¶ data available in 1000 patients</s></p></note></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cleland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Falk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>González-Juanatey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Harjola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Jankowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jessup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Linde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nihoyannopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Parissis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pieske</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Riley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Rosano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Ruilope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ruschitzka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Rutten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Der Meer</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC</title>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2129" to="2200" />
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
	<note>Authors/Task Force Members</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure</title>
		<author>
			<persName><forename type="first">R</forename><surname>Garg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yusuf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page" from="1450" to="1456" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The effect of carvedilol on morbidity and mortality in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">M</forename><surname>Packer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Bristow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Cohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Colucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Gilbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Shusterman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">334</biblScope>
			<biblScope unit="page" from="1349" to="1355" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Eplerenone in patients with systolic heart failure and mild symptoms</title>
		<author>
			<persName><forename type="first">F</forename><surname>Zannad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jjv</forename><surname>Mcmurray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Krum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Van Veldhuisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Swedberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vincent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Pocock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">364</biblScope>
			<biblScope unit="page" from="11" to="21" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Angiotensin-neprilysin inhibition versus enalapril in heart failure</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Mcmurray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Packer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Desai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Lefkowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Rizkala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Rouleau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Solomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Swedberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Zile</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">PARADIGM-HF Investigators and Committees</title>
				<imprint>
			<date type="published" when="2014">2014</date>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="993" to="1004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Maggioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Dahlström</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Chioncel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Leiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Drozdz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fruhwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gullestad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Logeart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Urso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Parissis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Persson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rauchhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">W</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zannad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tavazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Crespo</forename><surname>Leiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Drozdz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fruhwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gullestad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Logeart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Urso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Metra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Parissis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Persson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rauchhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">W</forename><surname>Zannad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tavazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="808" to="817" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Rosuvastatin in older patients with systolic heart failure</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kjekshus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Apetrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Barrios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Böhm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jgf</forename><surname>Cleland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cornel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dunselman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fonseca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Goudev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gullestad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hjalmarson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hradec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jánosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kamensky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Komajda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Korewicki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kuusi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mareev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jjv</forename><surname>Mcmurray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ranjith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schaufelberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vanhaecke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Van Veldhuisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Waagstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wedel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wikstrand</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="page" from="2248" to="2261" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">L</forename><surname>Tavazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Maggioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Marchioli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Barlera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Franzosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Latini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Nicolosi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Porcu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G; Gissi-Hf</forename><surname>Tognoni</surname></persName>
		</author>
		<author>
			<persName><surname>Investigators</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="1231" to="1239" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Statins in heart failure: the paradox between large randomized clinical trials and real life</title>
		<author>
			<persName><forename type="first">P</forename><surname>Gastelurrutia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lupón</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Antonio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Urrutia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Díez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Coll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altimir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bayes-Genis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mayo Clin Proc</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="555" to="560" />
			<date type="published" when="2012-06">2012 Jun</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Navarese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kolodziejczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kereiakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">S</forename><surname>Tantry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>O'connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gurbel</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review</title>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<date type="published" when="2016-05">2016 May</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">PCSK9: a key modulator of cardiovascular health</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Seidah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Awan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chrétien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mbikay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1022" to="1036" />
			<date type="published" when="2014-03-14">2014 Mar 14</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Shimada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Cannon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="2415" to="2424" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Nicholls</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Puri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Ballantyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Kastelein</surname></persName>
		</author>
		<author>
			<persName><surname>Koenig</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial</title>
		<author>
			<persName><forename type="first">W</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Somaratne</forename><forename type="middle">R</forename><surname>Kassahun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wasserman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ungi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Podolec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ophuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Cornel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Borgman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Nissen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="page" from="2373" to="2384" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Sabatine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Giugliano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Keech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Honarpour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Wiviott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Kuder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Wasserman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Sever</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Pedersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="1713" to="1722" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cleland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dickstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Der Harst</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Hillege</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ter Maaten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<imprint>
			<pubPlace>Samani NJ, van</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Veldhuisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zannad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Zwinderman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="716" to="726" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">E</forename><surname>Assarsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Holmquist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bjorkesten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bucht</forename><surname>Thorsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Ekman</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, specificity, and Excellent Scalability</title>
		<author>
			<persName><forename type="first">D</forename><surname>Eriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Rennel</forename><surname>Dickens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ohlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Edfeldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Lindstedt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stenvang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gullberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fredriksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0095192</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<date type="published" when="2014-04">April. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ouwerkerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zannad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Van Veldhuisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Samani</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ter Maaten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Hillege</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Der Harst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dickstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cleland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Zwinderman</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure</title>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="627" to="634" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title level="m" type="main">Multivariable Model-building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables</title>
		<author>
			<persName><forename type="first">P</forename><surname>Royston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<publisher>Wiley</publisher>
			<pubPlace>Chichester, UK</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Almontashiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Vilmundarson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ghasemzadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dandona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Roberts</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Quyyumi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e106294</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Oemrawsingh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Garcia-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Boersma</surname></persName>
		</author>
		<imprint>
			<pubPlace>Van Geuns R, Serruys</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<monogr>
		<title level="m" type="main">PCSK9 in relation to coronary plaque inflammation and cardiovascular outcome</title>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<imprint>
			<biblScope unit="volume">2015</biblScope>
			<biblScope unit="page" from="221" to="238" />
			<pubPlace>Rotterdam, the Netherlands</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Erasmus University Rotterdam</orgName>
		</respStmt>
	</monogr>
	<note>Coronary Artery Disease: From Atherosclerosis to Cardiogenic Shock</note>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Lagace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Garuti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mcdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Horton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Cohen</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growthfactor-likerepeatAoflowdensitylipoproteinreceptordecreasesreceptor recycling and increases degradation</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Hobbs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">282</biblScope>
			<biblScope unit="page" from="18602" to="18612" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Poirier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Benjanne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bergeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Marcinkiewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Nassoury</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2</title>
		<author>
			<persName><forename type="first">H</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nimpf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Prat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Seidah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">283</biblScope>
			<biblScope unit="page" from="2363" to="2372" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Lagace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Garuti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Mcnutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Prather</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">N</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Hammer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Horton</surname></persName>
		</author>
		<imprint>
			<biblScope unit="volume">21</biblScope>
		</imprint>
	</monogr>
	<note>Secreted PCSK9 decreases the number of</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">LDL receptors in hepatocytes and in livers of parabiotic mice</title>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="2995" to="3005" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Bensch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kowala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Alborn</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Konrad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="634" to="640" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Maxwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Breslow</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">ProcNatlAcad Sci USA</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="2069" to="2074" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects</title>
		<author>
			<persName><forename type="first">H</forename><surname>Tavori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rashid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fazio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">238</biblScope>
			<biblScope unit="page" from="264" to="270" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study</title>
		<author>
			<persName><forename type="first">W</forename><surname>Ouwerkerk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Voors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Cleland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dickstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Der Harst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Hillege</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ter Maaten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Samani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Van Veldhuisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zannad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Metra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Zwinderman</surname></persName>
		</author>
		<idno type="DOI">10.1093/eurheartj/ehx026</idno>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<date type="published" when="2017-03-11">2017 Mar 11</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects</title>
		<author>
			<persName><forename type="first">H</forename><surname>Tavori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rashid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fazio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">238</biblScope>
			<biblScope unit="page" from="264" to="270" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Dunlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Redfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Weston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Therneau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hall</forename><surname>Long</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Hospitalizations after heart failure diagnosis a community perspective</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Roger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1695" to="1702" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Ray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Landmesser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Leiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kallend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dufour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Karakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Troquay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Visseren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wijngaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Kastelein</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol</title>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">376</biblScope>
			<biblScope unit="page" from="1430" to="1440" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Cross-talkbetweenLOX-1andPCSK9invasculartissues</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shahanawaz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Res</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="556" to="567" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappa B activation in THP-1-derived macrophages</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J MolMed</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="931" to="938" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Pyrrolidine dithiocarbamate abrogates tissue factor (TF) expression by endothelial cells: evidence implicating nuclear factorB in TF induction by diverse agonists</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Orthner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Rodgers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Fitzgerald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="436" to="443" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">O</forename><surname>Bonsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Reidpath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kadirvelu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Drugs Ther</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="177" to="188" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Rauchhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Davos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bolger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><surname>Coats</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The relationship between cholesterol and survival in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">Anker</forename><surname>Aj</surname></persName>
		</author>
		<author>
			<persName><surname>Sd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="1933" to="1940" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Proprotein convertase subtilisin/kexin type 9 expression is transiently upregulated in the acute period of myocardial infarction in rat</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cardiovasc Disord</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">192</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Abifadel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Varret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Rabes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Allard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ouguerram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Devillers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cruaud</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Benjannet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wickham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Erlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Derre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Villeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Farnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Beucler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bruckert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chambaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chanu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lecerf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Luc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Moulin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Weissenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<imprint>
			<biblScope unit="page">23</biblScope>
			<pubPlace>Prat</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Mutations in PCSK9 cause autosomal dominant hypercholesterolemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Krempf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Junien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Seidah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Boileau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="154" to="156" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
